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Cardiovascular
RVLMCannabinoids elicit complex hemodynamic responses in experimental animals that involve both
peripheral and central sites. Centrally administered cannabinoids have been shown to predom-
inantly cause pressor response. However, very little is known about the mechanism of the can-
nabinoid receptor 1 (CB1R)-centrally evoked pressor response. In this review, we provided an
overview of the contemporary knowledge regarding the cannabinoids centrally elicited cardio-
vascular responses and the possible underlying signaling mechanisms. The current review
focuses on the rostral ventrolateral medulla (RVLM) as the primary brainstem nucleus impli-
cated in CB1R-evoked pressor response.
ª 2013 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Cannabinoids
Cannabinoids are heterogeneous group of compounds that
target cannabinoid receptors: CB1 and CB2. These compounds
include the naturally occurring D9-tetra-hydrocannabinol (D9-
THC), isolated from the plant Cannabis sativa (marijuana),
endogenous compounds known as endocannabinoids (ECs),
as well as other synthetic compounds. Since at least 2000
B.C., the plant Cannabis has been long used for recreationaland medical purposes. D9-THC, Cannabidiol (CBD), and can-
nabinol are the most abundant natural cannabinoids active at
CB1 and CB2 receptors, but only D
9-THC has an equal afﬁnity
for both CB1 and CB2 receptors [1,2]. The ﬁrst endogenous li-
gand for both cannabinoid receptors [2], anandamide, is a
derivative of arachidonic acid (arachidonoyl ethanolamide;
AEA), which was isolated from pig brain in 1992 [3], and 2-
arachidonoyl glycerol (2-AG) is another abundant ECs [4].
Most of the endogenous cannabinoids discovered so far are
agonists except the inverse agonist virodhamine [5]. The high
afﬁnity non-eicosanoid cannabinoids CP55940 and the ami-
no-alkyl-indole cannabinoid WIN55,212-2 were developed by
Pﬁzer and Sterling Winthrop, respectively. SR141716A and
AM251 are selective antagonists for the CB1R, while
SR144528 is selective for the CB2R [2,6]. Notably, most of
the synthetic compounds are highly lipophilic and water insol-
uble except for O-1057, which is highly water soluble and pos-
sesses comparable potency as CP55940 [7]. Hemopressin, a
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rized as inverse cannabinoid agonist [8,9].
Cannabinoid receptor 1
It is now known that cannabinoids exert their actions mainly
via two subtypes of G-protein-coupled receptors (GPCRs):
CB1 and CB2. Additional non-CB1, non-CB2 established
GPCRs, such as GPR55 and GPR18, are also targeted by
these compounds (e.g. anandamide, virodhamine, CP559440,
and AM251 but not WIN55,212-2) [10–14]. Our review focuses
on the CB1R, which is found primarily in the CNS, including
the cardiovascular regulatory nuclei in the brainstem. The CB1
receptor, a 473-amino-acid protein, was ﬁrst cloned from a rat
cerebral cortex cDNA library [15] and a human brainstem li-
brary [16], which maintains the essential topographical fea-
tures for a G-protein-coupled receptor (GPCR) of (i) seven
hydrophobic transmembrane domain regions that extend
through the plasma membrane; (ii) three extracellular loops;
(iii) three intracellular loops; (iv) an extracellular N-terminal;
(v) and an intracellular C-terminal [17].
CB1R signaling
Activation of CB1R triggers several downstream effectors
including inhibition of adenylyl cyclase, stimulation of in-
wardly rectifying potassium channels, inhibition of N- and
P/Q-type voltage-dependent calcium channels, and activation
of mitogen-activated protein kinase (MAPK) pathway. Can-
nabinoids acting via CB1R reduce cAMP production by inhib-
iting adenylyl cyclase [18–20] which is antagonized by
cannabinoid antagonists SR141716A and LY320135 [21].
These effects are mediated via inhibitory G-protein (Gai/o) be-
cause they were blocked by Gai/o-selective pertussis toxin in
mammalian brain and in cultured neuronal cells [18–20]. Many
other CB1R-mediated physiological functions are G-protein
Gai/o mediated [19,22,23]. However, the diverse, sometimes
opposing, CB1R-evoked physiological functions that are not
completely attributable to simply lowering intracellular cAMP
levels, have led to investigations of the role of other non-Gai/o
signaling mechanisms [24]. In this line, recent studies have
linked CB1R coupling to activation of Gaq/11 or Gas. It is pos-
sible that heterodimerization between the CB1R and other
receptor(s) contribute, at least partly, to this divergent signal
transduction. This notion is supported by the reported interac-
tion between CB1R and other co-localized receptors e.g. dopa-
mine D2R, which resulted in accumulation of cAMP [25,26].
Second, CB1R behaves as a Gaq/11-G-protein-coupled recep-
tor in cultured hippocampal neurons and trabecular meshwork
cells [24,27]. Further, the ﬁndings that heterodimerization be-
tween CB1R and OX1R resulted in enhanced Gaq/11-depen-
dent OX1R signaling in presence of CB1R [28].
Retrograde CB1R-mediated signaling
CB1R is located mostly presynaptically, thus playing crucial
roles in controlling the release of neurotransmitters at both
excitatory and inhibitory synapses. Upon depolarization, the
postsynaptically released endocannabinoids activate presynap-
tic CB1R, which in turn modulates the release of variousneurotransmitters [23,29]. For example, WIN55,212-2 inhib-
ited GABA release from presynaptic terminals in cultured hip-
pocampal or ventromedial medulla (RVM) neurons following
postsynaptic depolarization [30,31]. The latter effect was com-
pletely abolished in presence of selective CB1 receptor antago-
nists. This phenomenon is termed depolarization-induced
suppression of inhibition (DSI). Findings from cerebellar Pur-
kinje cells support the possibility that postsynaptically released
endocannabinoids act as retrograde secondary messengers at
both inhibitory as well as excitatory synapses because follow-
ing depolarization, the released endocannabinoids, which stim-
ulate presynaptic CB1R, ultimately suppress presynaptic
calcium-induced glutamate release [32]. The latter phenome-
non is termed depolarization-induced suppression of excitation
or (DSE). Both CB1R mediated DSE and DSI are considered
key mechanisms for many of the central effects of endogenous
and exogenous cannabinoids.
Cardiovascular effects of cannabinoids
The cardiovascular responses to cannabinoids are complex and
are dependent on the state of the studied animals (conscious
vs. anaesthetized) and the route of administration (systemic
vs. central) [33–38].
Systemic CB1R-evoked cardiovascular effects
In anesthetized animals, systemically administered cannabi-
noids elicit predominantly hypotension and bradycardia.
These effects are mediated peripherally through prejunctional
inhibition of sympathetic outﬂow and vagal stimulation result-
ing in reduction in BP and HR, respectively [39–42]. Systemic
administration of THC, anandamide, or WIN55,212-2 elicited
tri-phasic effects on BP in anesthetized rats: (i) an initial brief
hypotensive phase, secondary to a bradycardic response, which
was blocked by atropine pretreatment or vagotomy; (ii) a tran-
sient pressor response due to direct vasoconstriction; (iii) a
more predominant depressor phase. The prolonged depressor
phase was mediated via peripheral sympathoinhibition because
it was attenuated by cervical spinal transection and blockade
of a-adrenoceptors [39–43]. Interestingly, recent studies have
suggested that, in addition to the direct vasoconstrictor action
discussed above, the transient pressor response evoked by sys-
temic cannabinoids in anaesthetized animals might involve
central mechanisms [44,45]. However, the cardiovascular re-
sponses of systemically administered cannabinoids in con-
scious animals are quite different. The prolonged depressor
response (phase III) is absent following systemically injected
anandamide or WIN55,212-2 which, in contrast, cause pre-
dominate pressor responses along with bradycardia in con-
scious rats [36,37]. The elicited pressor response by systemic
WIN55,212-2 in conscious animals is centrally mediated be-
cause it was attenuated by ganglion blockade [37]. Impor-
tantly, in humans, acute administration of cannabinoid is
associated with tachycardia and a pressor response [46–48].
Central CB1R-evoked cardiovascular effects
Centrally administered cannabinoids predominantly elicit sym-
pathoexcitation/pressor responses. Studies have elucidated the
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responses elicited by central CB1R activation, e.g. Nucleus
Tractus Solitarii (NTS) and the rostral ventrolateral medulla
(RVLM) [39,49–52].
The NTS
The NTS is located in the brainstem ﬂanked on each side of the
fourth ventricle and consists of groups of cells in a column-like
structure dorsal to the RVLM and represents the ﬁrst relay sta-
tion in the baroreﬂex arc. Upon stimulation, the NTS elicits a
reduction in the BP, HR, and sympathetic outﬂow [53,54]. The
most cardiovascular-relevant part of the NTS is located at the
most caudal part of the NTS, which contains synapses from
chemo and aortic baroreceptor processes that contact with sec-
ondary order neurons within the NTS [55,56]. The latter com-
municate either directly or indirectly through third order
neurons with other nuclei including RVLM, hypothalamus
or CVLM [57–60]. Functionally, activation of cardiovascular
afferents (chemo or baroreceptors) enhances the release of
excitatory amino-acid L-glutamate within the NTS [54], which
prompts the excitation of NTS-projections to other baroreﬂex
arc nuclei e.g. RVLM and CVLM. Several reports have shown
important roles for activation of CB1R in the NTS in blood
pressure regulation [50–52,61]. For examples, activation of
NTS cannabinoid receptors by anandamide enhanced barore-
ﬂex-mediated sympathoinhibition, at least partly, via presyn-
aptic inhibition of GABA release [52,62].
The RVLM
In this review, attention has been focused on the RVLM,
which plays pivotal role in central control of cardiovascular
function [63–65]. The RVLM is the ﬁnal supraspinal site with-
in the central nervous system that integrates multitudes of
inﬂuences on blood pressure (BP) from higher brain regions
such as paraventricular nucleus, lateral hypothalamus, and
periaqueductal gray [64,66]. The RVLM is of high signiﬁcance
in controlling BP since bilateral lesioning of the RVLM leads
to a profound fall in BP [59]. The RVLM is located in the ven-
tral part of the brainstem, lateral to the inferior olive, caudal to
the facial nucleus, and ventral to the nucleus ambiguous
[59,67]. It is heterogeneous in composition and contains multi-
ple cell groups that are different in their neurochemical pheno-
type (e.g. rostroventrolateralis, gigantocellular nucleus, and
paragigantocellularis lateralis [68–71]. Within the RVLM, the
adrenergic group C1 neurons, alternatively known as adrener-
gic neurons, are deﬁned based on their expression of phenyl-
ethanolamine-n-methyltransferase (PNMT) [72,73]. The
rostral C1 subgroup contains barosensitive neurons which pro-
ject to the spinal cord [74,75] and provides tonic excitatory in-
puts to the sympathetic preganglionic neurons [76,77]. Beside
catecholamine-containing neurons in RVLM [78], a wide vari-
ety of neurotransmitters and receptors are present in the
RVLM including substance P [79], neuropeptide Y [80],
enkephalin [80,81], adenosine receptors (A2A) [82], P2X recep-
tors [83], Angiotensin II AT1 receptors [84], imidazoline I1receptors [85,86], a2A adrenergic receptors [87,88], cannabinoid
CB1 receptors [89,90], CB2 receptors [91], and mu-opioid
receptors [92,93]. The RVLM is a crucial brainstem nucleus
for the tonic generation of sympathetic nerve activity [59,60].
Activation of speciﬁc neurons within the RVLM causes an in-
crease in BP by increasing peripheral resistance and cardiac
output via released catecholamines [94–97]. In addition to car-
diovascular control, speciﬁc neurons within the RVLM are in-
volved in nociception [98,99] and breathing [100].
Intracisternal (i.c) administration [101–103] or intra-RVLM
microinjection [90,104] of cannabinoids such as WIN55,212-2
or CP-55940 elicited a pressor response and caused increases
in sympathetic nerve activity, plasma norepinephrine and
blood pressure, in conscious and anesthetized animals, and
these responses were attenuated by pretreatment with the
CB1R antagonists SR171416A or AM251. The signiﬁcant in-
crease in tyrosine hydroxylase immunoreactive neurons (TH-
ir) expressing c-Fos, a marker of neuronal activity, following
i.c. WIN55,212-2 provided direct in vivo evidence that central
CB1R-evoked pressor response involves activation of
RVLM-catecholaminergic neurons [102], which was abrogated
by CB1R antagonist AM251.
Centrally elicited hemodynamic effects of CB1R in conscious
Sprague Dawley rats
In our recent studies, we sought to elucidate the mechanisms
implicated in the central CB1R-evoked sympathoexcitation/
pressor response [102,104,105]. In pursuit of this goal, we char-
acterized the centrally mediated cardiovascular effects of cen-
tral CB1R activation in conscious Sprague Dawley rats. We
have conﬁrmed the expression of CB1R (protein) in the RVLM
by detecting the two bands at 64 and 53 kDa, which represent
the N-glycosylated and non-glycosylated forms of CB1R,
respectively (unpublished data) [106].
We reported that i.c. administration of WIN55,212-2 elicited
dose-dependent pressor responses and increased NE plasma lev-
els, denoting an increase in central sympathetic tone in conscious
rats [102], which agrees with ﬁndings in experimental animals dis-
cussed above [39,101,103], and reﬂects similar responses observed
in humans [47,48]. Similar pressor response was observed follow-
ing microinjection of WIN55,212-2, for the ﬁrst time, in the
RVLM of conscious freely moving rats [104]. These studies were
conducted in conscious rats to circumvent the negative impact of
anesthesia that was shown to dramatically compromise cannabi-
noid-evoked hemodynamic responses [36–38].
We demonstrated in our studies that the cardiovascular, bio-
chemical, and molecular responses elicited by WIN55,212-2 were
CB1R mediated. This is important because (i) WIN55,212-2,
which is routinely used in cannabinoid research, can also bind
to CB2R [107,108]; (ii) both CBR subtypes are expressed in the
brain [89,109], including the brainstem [90]. The ability of the
selective CB1R antagonist AM251 [39,101,103] to virtually abol-
ish the pressor, biochemical and neurochemical responses elicited
by i.c. WIN55,212-2 clearly implicates the CB1R in the observed
responses. It is important to note, however, that the lack of
change in blood pressure, as well as other neurochemical
140 B.M. Ibrahim and A.A. Abdel-Rahmanresponses, following AM251 administration argues against the
involvement of central CB1R signaling in tonic control of blood
pressure in conscious rats [102,104,105].
Signaling mechanisms involved in CB1R-evoked pressor response
in the RVLMRole of ERK1/2-PI3K/Akt signaling pathway
Cannabinoids are highly potent activators of extracellular-sig-
nal regulated kinase 1/2 (ERK1/2), which was evident in stably
transfected Chinese hamster ovary cells expressing human
CB1R. This effect was (i) abrogated by SR141716A; (ii) sensi-
tive to pertussis toxin; (iii) and independent of the cannabi-
noid-induced inhibition of cAMP production [110]. The
pivotal role of PI3K/Akt and ERK1/2 as potential down-
stream molecular mediators of the central CB1R-mediated
sympathoexcitation/pressor response as suggested by multiple
lines of evidence was demonstrated recently [105]. Central
administration of WIN55,212-2 (i.c.) signiﬁcantly elevated
pERK1/2 in the NTS and RVLM [105]. The involvement of
any CB2R role in these responses was precluded because of
the abrogation of the WIN55,212-2-mediated cardiovascular
and neurochemical responses by MEK-ERK1/2 inhibition
(PD98059) and attenuation of the concomitant activation of
ERK1/2 pathway by pretreatment with the selective CB1R
antagonist AM251 (i.c.). In view of the crucial role of brain-
stem pERK1/2 signaling in central control of blood pressure,
previous studies from our laboratory [82,86] and others [111–
113] suggest that brainstem ERK1/2 plays a bi-directional role
in central regulation of blood pressure. For example, in both
normotensive and hypertensive rats, inhibition of RVLM
ERK1/2 phosphorylation gradually lowered blood pressure
[111], and its rapid activation plays pivotal role in the angio-
tensin II-mediated pressor response [113,114]. In contrast, we
have previously shown that RVLM MEK-ERK1/2 signaling
activation underlies the central a2A adrenergic or imidazoline
evoked acute hypotensive response [82,86].
Studies on the neuroprotective and/or anti-oncogenic effects
of cannabinoids via PI3K/Akt signaling pathway have yielded
controversial results. First, intraperitoneal injection of D9-THC
activated PI3K/Akt pathway in mouse hippocampus, striatum,
and cerebellum via a mechanism that was ERK1/2-independent
[115]. Second, THC-mediated anti-cancer effect in human pros-
tate cells involved PI3K/AKT and ERK1/2 signaling pathway
activation [116]. On the other hand, it was demonstrated in multi-
ple cancer cell lines that CB1R activation down regulates both
PI3K/Akt and ERK1/2 signaling pathway [117,118]. Based on
the molecular ﬁndings from our studies, we concluded that the
effect of WIN55,212-2 on PI3K/Akt may contribute to the
enhancement of ERK1/2 phosphorylation because in the pres-
ence of the PI3K/Akt inhibitor wortmannin, WIN55,212-2-in-
duced ERK1/2 phosphorylation was exacerbated [105].
Additionally, PD98059, MEK-ERK1/2 inhibitor, alone or in
the presence of WIN55,212-2 had no effect on brainstem pAkt
phosphorylation levels.
Consistent with a diverse physiological role of PI3K/Akt-
ERK1/2 pathway, we showed that a dose-related reduction
in pAkt phosphorylation levels in the NTS and RVLM con-tributes to the i.c. WIN55,212-2-evoked pressor response
[105]. In support of this conclusion are the ﬁndings that the
inhibition of Akt phosphorylation in the NTS and RVLM pre-
ceded the peak WIN55,212-2-evoked pressor response (5 min).
Our Western blot ﬁndings are consistent with reported ﬁndings
that CB1R activation resulted in down-regulation of the PI3K/
Akt signaling [105,117,118]. However, others have shown that
CB1R activation up-regulated PI3K/Akt signaling in U373
MG human astrocytoma cells [119], hippocampal slices [120],
and in vivo [115]. Nonetheless, further support for a causal role
for the observed inhibition in Akt phosphorylation in the
brainstem in the central CB1R-mediated pressor response are
the ﬁndings that pharmacological inhibition of brainstem
PI3K-Akt signaling (wortmannin) signiﬁcantly enhanced the
WIN55,212-2 evoked dose-related pressor response [105].
Interestingly, the latter study reported an increase in Akt phos-
phorylation elicited by WIN55,212-2 following CB1R block-
ade with AM251 in the NTS but not in the RVLM. This
ﬁnding clearly highlights differences between neurochemical
responses elicited by CB1R activation in the RVLM vs. NTS.CB1R enhances RVLM nNOS-NO signaling pathway
The well-documented role of NOS-NO signaling in the RVLM
regulation of autonomic function has led us to investigate
whether nNOS-NO plays a signiﬁcant role in the central
CB1R-mediated pressor response [104,121–123]. We reported
that intra-RVLM WIN55,212-2 microinjection elicited dose-
dependent increases in real-time RVLM NO and blood pres-
sure; NO was measured by in vivo electrochemistry and is pos-
sibly nNOS-generated because: (i) parallel to the WIN55,212-2
dose-dependent enhancement of NO release, we detected a sig-
niﬁcant increase in nNOS phosphorylation in the WIN55,212-
2-treated RVLM compared to the contra-lateral side (control);
(ii) i.c. WIN55,212-2 increased the number of nNOS-ir neu-
rons expressing c-Fos, denoting an increase in the activity of
nNOS expressing neurons; (iii) these neurochemical responses
were abolished following selective CB1R blockade (AM251) or
prior inhibition of nNOS phosphorylation (NPLA) [104]; (iv)
only RVLM nNOS, but not eNOS or iNOS, derived NO is
implicated in centrally evoked hypertension [123]. Because
ERK1/2 dependent phosphorylation of RVLM nNOS is impli-
cated in sympathoexcitation [124–126], the interesting possibil-
ity exists that CB1R-mediated nNOS activation might be
downstream to MEK-ERK1/2 activation, which ultimately re-
sults in CB1R-mediated pressor response.
CB1R downregulates brainstem GABAergic transmission
It is highly likely that central CB1R-elicited sympathoexcita-
tion is mediated via indirect modulation of presympathetic
neurons in the brainstem whose activity is regulated by an ar-
ray of tonic excitatory and inhibitory inputs [90,127]. Notably,
CB1R modulates synaptic transmission of both inhibitory
(GABA) and excitatory (glutamate) neurotransmitters
[23,29,128,129]. Interestingly, stimulation of central GABAA
receptors (muscimol) caused the following: (i) abolished the
CB1R-evoked pressor response and the elevation in plasma
NE; (ii) attenuated the WIN55,212-2 evoked increase in the
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are consistent with reported in vitro ﬁndings that demonstrated
CB1R-evoked inhibition of GABAergic transmission in cul-
tured rostral ventromedial medulla (RVM) neurons [31]. Yet,
in the NTS, studies have demonstrated a controversial role
for CB1R-mediated presynaptic modulation of excitatory (glu-
tamate) and inhibitory (GABA) neurotransmitters. Ananda-
mide increased baroreﬂex-mediated sympathoinhibition in
the NTS, presumably, via presynaptic inhibition of GABA re-
lease because the response was reversed in presence of the GA-
BAAR antagonist [52].
Conclusions
As summarized in Fig. 1, the present review highlights the
molecular mechanisms implicated in the predominant sympat-
hoexcitatory effect of brainstem CB1R activation in conscious
rats. CB1R stimulation enhanced neuronal activity of presym-
pathetic neurons in the RVLM (c-Fos/TH-ir ratio). Further-
more, PI3K/Akt-ERK1/2 signaling in the brainstem seems to
differentially contribute, at least in part, to the sympathoexcit-
atory responses elicited by the central CB1R activation in con-
scious rats. The discussed studies demonstrated that CB1RFig. 1 Schematic presentation of signaling mechanisms in the
rostral ventrolateral medulla (RVLM) catecholaminergic C1 area,
underlying central CB1R-mediated pressor response. In conscious
freely moving rats, central CB1R activation (WIN55,212-2)
increases blood pressure, plasma norepinephrine (NE), sympa-
thetic neuronal activity (SNA) [102], enhances ERK1/2 and nNOS
phosphorylation (NO production) and reduces Akt phosphoryla-
tion in the RVLM [104,105]. AM251 (CB1R antagonist); NPLA
(nNOS inhibitor); PD98059 (MEK-ERK1/2 inhibitor) or musci-
mol (GABAA receptor agonist) attenuated CB1R (WIN55,212-2)-
evoked pressor response [102,104,105]. In contrast, wortmannin
(PI3K-Akt inhibitor) exaggerated WIN55,212-2 response [105].
The proposed model system is further supported by our neuro-
chemical and pharmacological ﬁndings following intracisternal or
intra-RVLM microinjection of the CB1R agonist WIN55,212-2
[104,105]. Solid arrows indicate signaling based on reported in vivo
ﬁndings, while dashed arrows indicate proposed signaling based
on reported in vitro ﬁndings, but not tested in this model (see text
for details).activation in the RVLM elicits down-regulation of PI3K/Akt
pathway along with the pressor response, which was supported
by the exacerbation of WIN55,212-2 evoked hemodynamic re-
sponses when PI3K/Akt was inhibited by wortmannin. By
contrast, the CB1R-evoked sympathoexcitation was associated
with enhanced ERK1/2 activity in the brainstem. Further, sup-
pressing ERK1/2 signaling abolished the central CB1R-evoked
pressor response. Finally, CB1R activation in the RVLM en-
hanced neuronal nitroxidergic activity (nNOS-NO) essential
for the central regulation of cardiovascular function. These lat-
ter neuronal responses may be linked to the modulation of
brainstem GABAergic neurotransmission and subsequently
to the central CB1R-evoked sympathoexcitatory and pressor
response. It is imperative to note that this overview highlights
important signaling networks implicated in the modulation of
blood pressure caused by central CB1R activation in normo-
tensive rats. The neurochemical and molecular responses dis-
cussed above might be different under pathophysiological
conditions and might, therefore, lead to different cardiovascu-
lar outcomes. Therefore, future studies on the role of central
CB1R signaling in animal models of human diseases are
warranted.Conﬂict of interest
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